MARKET

TARA

TARA

Protara Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.96
-0.11
-1.09%
After Hours: 9.99 +0.03 +0.30% 19:38 06/11 EDT
OPEN
10.04
PREV CLOSE
10.07
HIGH
10.32
LOW
9.89
VOLUME
59.04K
TURNOVER
--
52 WEEK HIGH
40.29
52 WEEK LOW
8.54
MARKET CAP
111.84M
P/E (TTM)
-2.2293
1D
5D
1M
3M
1Y
5Y
Protara Therapeutics Announces Appointment of Jane Huang, M.D. to Board of Directors
NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the appointment ...
GlobeNewswire · 3d ago
2 Falling Knives to Catch
GuruFocus News · 06/04 14:36
Benzinga's Top Ratings Upgrades, Downgrades For June 4, 2021
 
Benzinga · 06/04 14:03
Protara trades higher as H.C. Wainwright highlights potential of lead asset
Protara Therapeutics (TARA) has surged in early hours with a gain of ~6.1% as H.C. Wainwright analyst Andrew S. Fein initiates the coverage with a buy rating and a price target of
Seekingalpha · 06/04 13:28
DOCU, CLNE, KNDI and SENS among premarket gainers
Senseonics Holdings SENS +34% on the study results for glucose monitoring system.Windtree Therapeutics (WINT) +28%.The9 Limited NCTY +18% on Montcrypto acquisition.SemiLEDs Corporation (LEDS) +16%.Q&K International Group Limited (QK) +15%.Core Laboratories...
Seekingalpha · 06/04 12:21
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Benzinga · 06/04 12:11
--HC Wainwright Starts Protara Therapeutics at Buy With $40 Price Target
MT Newswires · 06/04 07:05
Seeking Alpha Catalyst Watch
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a
Seekingalpha · 05/14 19:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TARA. Analyze the recent business situations of Protara Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TARA stock price target is 41.20 with a high estimate of 50.00 and a low estimate of 32.00.
EPS
Institutional Holdings
Institutions: 66
Institutional Holdings: 11.82M
% Owned: 105.29%
Shares Outstanding: 11.23M
TypeInstitutionsShares
Increased
19
620.79K
New
5
365.05K
Decreased
9
330.82K
Sold Out
5
902.90K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.29%
Pharmaceuticals & Medical Research
-0.72%
Key Executives
Non-Executive Chairman/Independent Director
Luke Beshar
President/Chief Executive Officer/Director
Jesse Shefferman
Chief Financial Officer
Blaine Davis
Chief Operating Officer/Chief Scientific Officer
Jacqueline Zummo
Vice President/IR Contact Officer
Justine O'Malley
Other
Martin Olivo
Director
Jane Huang
Independent Director
Barry Flannelly
Independent Director
Roger Garceau
Independent Director
Richard Levy
Independent Director
Gregory Sargen
Independent Director
Cynthia Smith
Independent Director
Michael Solomon
No Data
About TARA
Protara Therapeutics Inc., formerly ArTara Therapeutics Inc., is a clinical-stage company. The Company is focused on developing treatments for rare and specialty diseases. Its development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. Its product pipeline includes TARA 002 and IV choline chloride for injection. TARA 002 is its lead program focused on the treatment of Lymphatic Malformations (LMs). TARA 002 is a cellular therapy based on OK-432, also known as Picibanil, which is derived from a genetically distinct strain of Streptococcus Pyogenes. IV choline chloride is an enzyme replacement therapy for patients with choline deficiency who exhibit symptoms of liver impairment. IV Choline Chloride is being developed for the treatment of Intestinal Failure Associated Liver Disease (IFALD).

Webull offers kinds of Protara Therapeutics Inc stock information, including NASDAQ:TARA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TARA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TARA stock methods without spending real money on the virtual paper trading platform.